Omalizumab as adjuvant therapy for pemphigus vulgaris

Dermatol Ther. 2022 Aug;35(8):e15646. doi: 10.1111/dth.15646. Epub 2022 Jun 29.

Authors

Antonio Ji-Xu¹, Kimberly Artounian¹, Maxwell A Fung¹, Stephanie T Le¹, Emanual Maverakis¹

Affiliation

¹ Department of Dermatology, University of California, Davis, Sacramento, California, USA.

PMID: 35716013
DOI: 10.1111/dth.15646

No abstract available

Publication types

Letter

MeSH terms

Combined Modality Therapy
Glucocorticoids
Humans
Immunosuppressive Agents
Omalizumab / therapeutic use
Pemphigus* / diagnosis
Pemphigus* / drug therapy

Substances

Glucocorticoids
Immunosuppressive Agents
Omalizumab